The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Giles Named Deputy Director of Lurie Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FRANCIS GILES was named deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Giles will oversee Northwestern Medicine’s clinical research cancer programs and developmental therapeutics initiatives.

Giles previously served as the Lurie Cancer Center’s associate director for translational research and developmental therapeutics, and has been director of the Northwestern Medicine Developmental Therapeutics Institute since 2013. He is also a fellow of the Royal College of Physicians of Ireland, the Royal College of Pathologists, and the European Academy of Cancer Sciences.

“We have ambitious goals for the next few years, and our rapidly evolving translational programs will establish the Lurie Cancer Center as a national and international destination for tailored developmental therapeutics,” Giles said.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
By Claire Marie Porter and Paul Goldberg
Guest Editorial

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
By Kathy Davy
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account